Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Xiamen Innovex Therapeutics
Xiamen, Fujian, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Innovax has successfully commercialized the world’s first recombinant Hepatitis E vaccine (Hecolin®), a bivalent HPV vaccine (Cecolin®), and a 9-valent HPV vaccine (Cecolin®9) with WHO prequalification and international registrations. Cervical cancer and genital warts vaccines are in ongoing Phase III and II trials, respectively. Additional vaccines for other infectious diseases are in clinical or preclinical trials.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Recombinant proteinVaccine
- Industry
- Biotech
02
Partnerships
National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD)Beijing Tiantan Biological Products
Beyond the preview
Go deeper on Xiamen Innovex Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xiamen Innovex Therapeutics.